First Tracks Biotherapeutics, Inc. Stock: price and insider trades · United States
First Tracks Biotherapeutics, Inc.: what insiders have been doing
First Tracks Biotherapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (29 October 2025 to 29 October 2026), 5 filings came from 4 insiders.
Only sales appear on the open market, 2 sales in all totalling €56.7M, filed by 2 insiders. Biggest ticket of the year: €55.2M, sold by EcoR1 Capital, LLC and made public on 22 April 2026 (4.1% of market cap).
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 3,169 companies) published 24 filings over the same period, against 5 filings here. Since 2026, the database holds no purchases and 2 sales by insiders of the company.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleAnalyst consensus: bullish or bearish?
Analysts rate First Tracks Biotherapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$74.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
- 1,300 shares0Common StockSEC:0001477384-26-000012:0
- 39,265 shares@ US$5.740.014% mcap11.4% of flowCommon StockSEC:0001715429-26-000007:0
- 39,265 shares@ US$44.77640.11% mcap88.6% of flowCommon StockSEC:0001715429-26-000007:1
- 4,705,575 shares@ US$13.81344.14% mcap100.0% of flowCommon StockSEC:0000935836-26-000208:0
- 100 sharesCommon Stock, par value $0.001 per shareSEC:0001370053-26-000005:0
5 of 5 declarations
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) is a United States-based, clinical-stage biotechnology company listed on the NASDAQ market. The company began regular-way trading on April 20, 2026, following its separation from AnaptysBio. It launched with an initial capital structure designed to support roughly a two-year operating runway, which is meaningful for investors because it gives management time to advance the pipeline before near-term financing pressure becomes the dominant issue. As a newly independent public biotech, First Tracks is still in the value-creation phase, with market perception likely to be driven primarily by clinical execution rather than by commercial fundamentals.
The company’s core business is the development of antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. This places First Tracks in the specialized immunology segment of the biopharmaceutical industry, where scientific differentiation, clinical data quality and speed of development are critical. The company is targeting large but still underserved therapeutic areas across gastroenterology, rheumatology, dermatology and respiratory disease. From a competitive standpoint, that means it is operating in a crowded field of established large-cap pharma and innovative biotech peers, but with a focused pipeline intended to create a sharper scientific identity.
Read moreShow less
First Tracks’ lead programs include ANB033, a CD122 antagonist that targets the shared beta subunit of the IL-2 and IL-15 receptors and is being developed in celiac disease and eosinophilic esophagitis; rosnilimab, a first-in-class antibody designed to selectively deplete pathogenic T cells and evaluated in rheumatoid arthritis; and ANB101, a BDCA2-modulating antibody aimed at plasmacytoid dendritic cells. The portfolio is cohesive around immune modulation, which supports the company’s strategic narrative, but it also concentrates risk in a single therapeutic theme. For equity investors, that means upcoming trial readouts matter disproportionately.
Headquartered in San Diego, California, at 10770 Wateridge Circle, Suite 210, First Tracks is primarily a U.S. operating company at this stage, with its research, development and corporate infrastructure centered in the United States. Its current market position is best described as emerging and pipeline-driven rather than commercial-scale. There is no mature product revenue base yet; instead, the investment thesis rests on translational science, clinical proof-of-concept and capital efficiency.
Recent milestones are important. On May 14, 2026, the company reported first-quarter 2026 financial results and business updates, including that it launched with $180 million in cash and cash equivalents. Management also reiterated a focus on ANB033 and signaled plans to advance Phase 2 studies across multiple indications after Phase 1b data. For investors, TRAX represents a classic high-risk/high-upside NASDAQ biotech story: scientifically focused, early in its independent public life, and heavily dependent on clinical milestones and execution discipline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
